Inhibition of HER2‐Positive Breast Cancer Growth by Blocking the HER2 Signaling Pathway with HER2‐Glycan‐Imprinted Nanoparticles

Dong, Yueru; Li, Wei; Gu, Zikuan; Xing, Rongrong; Ma, Yanyan; Zhang, Qi; Liu, Zhen

doi:10.1002/ange.201904860

Cited by 39 publications

(26 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This idea follows the rationale reported for other drug targets, such as Her-2 (50-52). In addition, approaches aiming at inducing cell toxicity based on oncogene expression are already used in other tumor models, such as in Her2-positive breast, gastric and esophageal cancer, in which distinct strategies have been proposed to block Her2-induced tumor growth (53)(54)(55).…”

Section: Discussionmentioning

confidence: 99%

Osteopontin‑c isoform inhibition modulates ovarian cancer cell cisplatin resistance, viability and plasticity

et al. 2020

View full text Add to dashboard Cite

Osteopontin (OPN) is upregulated in several types of tumor and has been associated with chemoresistance. However, the contribution of OPN splicing isoforms (OPN-SIs) to chemoresistance requires further investigation. The present study aimed to evaluate the expression patterns of each tested OPN-SI in cisplatin (CDDP)-resistant ovarian carcinoma cell lines, focusing on the role of the OPN-c isoform (OPNc) in drug resistance. ACRP ovarian cancer cells resistant to CDDP, as well as their parental cell line A2780, were used. Analyses of the transcriptional expression of OPN-SIs, epithelial-mesenchymal transition (EMT) markers and EMT-related cytokines were performed using reverse transcription-quantitative PCR. OPNc was silenced in ACRP cells using anti-OPNc DNA oligomers and stably overexpressed by transfecting A2780 cells with a mammalian expression vector containing the full length OPNc cDNA. Functional assays were performed to determine cell proliferation, viability and colony formation. The results demonstrated that among the three tested OPN-SIs, OPNc was the most upregulated transcript in the ACRP cells compared with the parental A2780 cells. In addition, the expression levels of P-glycoprotein multidrug transporter were upregulated in CDDP-resistant ACRP cells compared with those in A2780 cells. OPNc knockdown sensitized ACRP cells to CDDP treatment and downregulated P-gp expression levels compared with those in the negative control group. Additionally, silencing of OPNc impaired cell proliferative and colony formation abilities, as well as reversed the expression levels of EMT markers and EMT-related cytokines compared with those in the negative control cells. Notably, although stable OPNc overexpression resulted in increased A2780 cell proliferation, it notably increased CDDP sensitivity compared with that in the cells transfected with a control vector. These results suggested that OPNc silencing may represent a putative approach to sensitize resistant ovarian cancer cells to chemotherapeutic agents.

show abstract

Section: Discussionmentioning

confidence: 99%

Osteopontin‑c isoform inhibition modulates ovarian cancer cell cisplatin resistance, viability and plasticity

et al. 2020

View full text Add to dashboard Cite

show abstract

“…3 Her2, a member of the transmembrane epidermal growth factor receptor family, is found to be overexpressed in approximately 25–30% of human primary breast cancers, associated with aggressive tumor behavior, higher remote metastasis, and poor clinical outcomes. 4,5 Moreover, it is found that Her2-positive breast cancers are prone to resistance to chemotherapy or hormone therapy. 3,6 Therefore, we envisaged an early stage, precise, targeted therapies for Her2-positive breast cancer, while monitoring and evaluating the treatment process in a timely manner.…”

Section: Introductionmentioning

confidence: 99%

Targeted gold nanoshelled hybrid nanocapsules encapsulating doxorubicin for bimodal imaging and near-infrared triggered synergistic therapy of Her2-positve breast cancer

et al. 2020

View full text Add to dashboard Cite

A multifunctional targeted nanoplatform combining photothermal therapy and chemotherapy has emerged as a promising strategy for comprehensive therapies of breast cancer. In this study, we constructed human epidermal growth factor receptor 2 (Her2)-targeted gold nanoshelled poly(lactic- co-glycolic acid) hybrid nanocapsules encapsulating perfluorooctyl bromide, superparamagnetic iron oxide nanoparticles, and doxorubicin (Her2-GPDH nanocapsules) as theranostic agent for bimodal ultrasound/magnetic resonance imaging and synergistic photothermal-chemotherapy of Her2-postive breast cancer cells. Her2–GPDH nanocomposites possessed well-defined spherical morphology, and the average diameter was about 296 nm with good dispersion. Targeting assays demonstrated that Her2–GPDH nanocapsules exhibited higher targeting binding to Her2-positive SKBR3 cells than Her2-negative MDA-MB-231cells. The encapsulation efficiency and the loading content of doxorubicin in Her2–GPDH nanocapsules were 39 ± 1.45% and 3.8 ± 0.52%, respectively, and the agent exhibited pH-responsive and near-infrared light-triggered stepwise release behavior of doxorubicin. In vitro, the agent had potential to serve as feasible candidate for ultrasound imaging and T2-weighted magnetic resonance imaging with a relatively high relaxivity. Cell experiments confirmed that the agent had significant photothermal cytotoxicity on SKBR3 cells, and the combined photothermal–chemotherapy could significantly enhance the anti-tumor effect. In summary, the present Her2–GPDH nanocapsules, a novel multifunctional nanoplatform, will offer a new way for early bimodal molecular-level diagnosis and synergistic treatment of Her2-positve breast cancer.

show abstract

“…Worth mentioning is the challenge of producing nanoMIP architectures suitable to translating MIP-mediated cell-recognition from the passive stage of binding to its defined target, to the active intervention in the cell biology process. To accomplish this important step,the integrated design of MIPs with multi-functions is expected, gathering in a single nanoMIP particle ability to activate or silence biochemical pathways[37,120]. The success in this area will result and in new paradigms for MIP applications both complementing existing therapeutic and diagnostic techniques and opening doors to in situ programmed nanomachines for precision medicine interventions and tissue regeneration.…”

mentioning

confidence: 99%

Molecularly Imprinted Polymers for Cell Recognition

Piletsky

Canfarotta²,

Poma

et al. 2020

Trends in Biotechnology

205

106

View full text Add to dashboard Cite

Since their conception fifty years ago, molecularly imprinted polymers (MIPs) have seen extensive development both in terms of synthetic routes and applications. Perhaps the most challenging target for molecular imprinting are cells. Though early work was based almost entirely around microprinting methods, recent developments shifted towards epitope imprinting to generate MIP nanoparticles. Simultaneously, the development of techniques such as solid phase MIP synthesis have solved many historic issues of MIP production. This review briefly describes various approached used in cell imprinting with a focus on applications of the created materials in imaging, drug delivery, diagnostics and tissue engineering.

show abstract

Inhibition of HER2‐Positive Breast Cancer Growth by Blocking the HER2 Signaling Pathway with HER2‐Glycan‐Imprinted Nanoparticles

Cited by 39 publications

References 49 publications

Osteopontin‑c isoform inhibition modulates ovarian cancer cell cisplatin resistance, viability and plasticity

Osteopontin‑c isoform inhibition modulates ovarian cancer cell cisplatin resistance, viability and plasticity

Targeted gold nanoshelled hybrid nanocapsules encapsulating doxorubicin for bimodal imaging and near-infrared triggered synergistic therapy of Her2-positve breast cancer

Molecularly Imprinted Polymers for Cell Recognition

Contact Info

Product

Resources

About